Cardiovascular Health

The Pharmacy Times® Cardiovascular Health resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The work and expertise of a drug utilization pharmacist should be empowered and integrated earlier into a recall process.
[[thumbnail_alt_text]]
Paul Dobesh, PharmD, and James Groce III, PharmD, provide some final thoughts on the future of CAD/PAD management.
[[thumbnail_alt_text]]
Nearly 30% of the 2773 patients with COVID-19 received systemic coagulation during their time in the hospital.
[[thumbnail_alt_text]]
Key opinion leaders discuss the need to educate patients and physicians and the potential consequences of managing CAD/PAD without proper data support or understanding.
[[thumbnail_alt_text]]
Experts in the field of CAD/PAD management provide personal insight into interchanging anticoagulants and minimizing confusion of the different DOACs at 2.5-mg strength. 
[[thumbnail_alt_text]]
The statement is one of the first from the AHA to focus on providing evidence-based strategies for parents and caregivers to create a healthy food environment for young children.
[[thumbnail_alt_text]]
Top pharmacists consider the reasons for delays in implementing new data into the treatment guidelines for CAD/PAD.
[[thumbnail_alt_text]]
Evolocumab, when used with diet, can be used as monotherapy or in combination with other lipid-lowering agents for the prevention of cardiovascular events.
[[thumbnail_alt_text]]
According to a study, men have higher concentrations of ACE2 in their blood than women, which may be a potential explanation for why men are more susceptible to COVID-19.
[[thumbnail_alt_text]]
At the end of 5 years, the teens with either obesity, T2D, or high systolic blood pressure were significantly more likely to have thicker and stiffer carotid arteries, the main blood vessel that leads to the brain, according to the study.
 
[[thumbnail_alt_text]]
A phase 3 trial showed a statistically significant and clinically meaningful decline in CV death or hospitalization from heart failure with dapagliflozin compared with placebo. 
[[thumbnail_alt_text]]
Lifestyle classes, or cardiac rehabilitation, are typically offered to heart attack patients unless the patient has a particular reason why it is not suitable for them.